Summary
Johnson & Johnson (JNJ) has entered into a definitive agreement to acquire Actelion Ltd. through an all-cash tender offer for USD280 per share. This significant transaction involves a two-part structure: JNJ will acquire Actelion's marketed products and late-stage clinical development assets, while Actelion's drug discovery operations and early-stage assets will be spun off into a new, publicly traded Swiss biopharmaceutical company, R&D NewCo. This demerger will occur immediately prior to the acquisition, with Actelion shareholders receiving shares in R&D NewCo as a dividend in kind. This strategic move signals JNJ's intent to bolster its pharmaceutical pipeline, particularly in areas with high growth potential. The acquisition of Actelion's established products and promising early-stage assets, combined with the creation of R&D NewCo to house the more speculative research, allows JNJ to access innovative therapies while mitigating some of the inherent risks associated with early-stage drug development. The deal is subject to customary closing conditions, including regulatory approvals and a high tender acceptance rate from Actelion shareholders.
Key Highlights
- 1Johnson & Johnson to acquire Actelion Ltd. for USD280 per share in an all-cash tender offer.
- 2Transaction involves a demerger of Actelion's early-stage R&D assets into a new independent company (R&D NewCo).
- 3Actelion shareholders will receive shares in R&D NewCo as a dividend in kind before the acquisition.
- 4R&D NewCo will be listed on the SIX Swiss Exchange and will receive significant funding, including a convertible note facility from a JNJ affiliate.
- 5JNJ's pharmaceutical segment is expected to be enhanced by Actelion's marketed products and late-stage pipeline.
- 6The deal includes customary closing conditions, such as regulatory approvals and a minimum tender threshold of two-thirds of Actelion shares.
- 7JNJ secures an option on ACT-132577, a resistant hypertension drug candidate within R&D NewCo, through a collaboration agreement.